Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	25.37B -36.9%
Revenue (ttm)	5.99B -2.2%
Net Income	972.56M -34.1%
EPS	0.49 -34.1%
Shares Out	1.98B
PE Ratio	26.37
Forward PE	35.06
Dividend	0.20 (1.56%)
Ex-Dividend Date	Jul 24, 2026

Volume	12,498,402
Open	12.71
Previous Close	12.83
Day's Range	12.65 - 12.83
52-Week Range	11.12 - 22.08
Beta	0.22
Analysts	Buy
Price Target	18.70 (+45.75%)
Earnings Date	Aug 29, 2026

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,205
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2025, SHA:600161's revenue was 6.17 billion, an increase of 2.26% compared to the previous year's 6.03 billion. Earnings were 1.09 billion, a decrease of -29.59%.

Analyst Summary

According to 4 analysts, the average rating for 600161 stock is "Buy." The 12-month stock price target is ¥18.70, which is an increase of 45.75% from the latest price.

Price Target

¥18.70

(45.75% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error